TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01188096
Drug: Poly ICLC
Normalized name: Poly iclc
DrugBank: Hiltonol (DB17293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Children will receive poly-ICLC 20 mcg/kg twice weekly IM (using Monday/Wednesday schedule if possible). The first 2 doses will be administered in the clinic under supervision.
Study: NCT00144274
Drug: Ambroxol Lozenge
Normalized name: ambroxol Lozenge Product
DrugBank: Ambroxol (DB06742)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00446381
Drug: Macugen (pegaptanib)
Normalized name: pegaptanib
DrugBank: Pegaptanib (DB04895)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pegaptanib 0.3 mg by intravitreal injection once pre-operatively
Study: NCT00446381
Drug: Macugen (Pegaptanib)
Normalized name: pegaptanib
DrugBank: Pegaptanib (DB04895)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pegaptanib 0.3 mg by intravitreal injection once pre-operatively.
Study: NCT03220490
Drug: IOP reduction of Brimonidine and Timolol with time interval
Normalized name: brimonidine / timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: In the selected eye the subject will be given two types of IOP reduction drops: first Brimonidine, Alphagan® (an alpha-agonist) followed by Timolol, Tiloptic® (a beta-blocker). The drops will be given with a time interval of five minutes between the first and second drop.
Study: NCT03220490
Drug: IOP reduction of Brimonidine and Timolol no time interval
Normalized name: brimonidine / timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: In the selected eye the subject will be given two types of IOP reduction drops:first Brimonidine, Alphagan® (an alpha-agonist) followed by Timolol, Tiloptic® (a beta-blocker). The drops will be given one after the other with no waiting period.
Study: NCT00894231
Drug: levocetirizine (Xyzal)
Normalized name: levocetirizine Oral Tablet [Xyzal]
DrugBank: Levocetirizine (DB06282)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5mg po QD
Study: NCT01964781
Drug: saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02162784
Drug: Budesonide/Procaterol, 180/10mcg X1
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: one puff
Study: NCT02162784
Drug: Budesonide/procaterol 180/10 mcg X 2
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2 puffs
Study: NCT02162784
Drug: Albuterol HFA MDI 100mcg X2
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFA MDI, 100mcg, 2 puffs
Study: NCT02633137
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02633137
Drug: high-dose cytarabine (HIDAC)
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02954354
Drug: Baloxavir Marboxil
Normalized name: Baloxavir Marboxil
DrugBank: Baloxavir marboxil (DB13997)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2 to4 X 20-mg tablets taken orally
Study: NCT02954354
Drug: Placebo to Baloxavir Marboxil
DrugBank: Baloxavir marboxil (DB13997)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2 to4 X 20-mg tablets taken orally
Study: NCT02954354
Drug: Oseltamivir
Normalized name: Oseltamivir
DrugBank: Oseltamivir (DB00198)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 mg capsules taken orally
Study: NCT02954354
Drug: Placebo to Oseltamivir
DrugBank: Oseltamivir (DB00198)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo capsules matching oseltamivir 75 mg capsules
Study: NCT03697109
Drug: Relacorilant
Normalized name: Relacorilant
DrugBank: Relacorilant (DB14976)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relacorilant is supplied as 100 mg capsules for oral dosing.
Study: NCT02195232
Drug: Isoquercetin
Normalized name: Isoquercetin
DrugBank: Isoquercetin (DB12665)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04495179
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subjects will receive intravenous durvalumab every 4 weeks for Arm A and every 3 weeks for Arm B.
Study: NCT04495179
Drug: Cabazitaxel
Normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive intravenous cabazitaxel every 3 weeks
Study: NCT01270347
Drug: MP-376 (Levofloxacin Solution for Inhalation)
Normalized name: 6 MP
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MP-376 (Aeroquin, Levofloxacin solution for Inhalation) 240 mg administered BID for 28-days treatment followed by 28 days off treatment
Study: NCT01270347
Drug: TIS (Tobramycin Inhalation Solution)
Normalized name: tobramycin Inhalation Solution
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tobramycin Inhalation Solution administered BID over 3 consecutive cycles of 28-days treatment followed by 28 days off treatment
Study: NCT04508439
Drug: Enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identify the benefit of different doses of low molecular weight heparin (enoxaparin) on the established clinical response due to lack of ventilatory support, length of hospital stay or death in patients requiring hospital care for COVID-19 infection.
Study: NCT02453581
Drug: OZ439
Normalized name: Artefenomel
DrugBank: Artefenomel (DB11809)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OZ439 Powder for Oral Suspension
Study: NCT03628521
Drug: Anlotinib，Erlotinib，IBI308，Pemetrexed，gemcitabine，carboplatin
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patient harboring EGFR mutation will be enrolled into arm A. Patients without sensitive EGFR mutation will be assigned to either arm B or arm C based on patients' or treating physicians'choice
Study: NCT01916707
Drug: Dosing of enoxaparin for VTE prophylaxis
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00210795
Drug: epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04320277
Drug: Baricitinib
Normalized name: baricitinib
DrugBank: Baricitinib (DB11817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Baricitinib 4 mg/day/orally combined to antiviral therapy ritonavir for 2 weeks. Baricitinib tablets 4 mg were administered in the morning.
Study: NCT00413387
Drug: beclomethasone dipropionate plus formoterol fumarate combination
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mcg beclomethasone diproprionate plus 6 mcg formoterol
Study: NCT00413387
Drug: budesonide plus formoterol combination
Normalized name: budesonide / formoterol
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 200mcg budesonide plus 6 mcg formoterol
Study: NCT00067015
Drug: bicalutamide
Normalized name: Bicalutamide
DrugBank: Bicalutamide (DB01128)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00067015
Drug: goserelin acetate
Normalized name: Goserelin Acetate
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00449176
Drug: tapentadol (CG5503) ER
Normalized name: tapentadol Extended Release Oral Tablet
DrugBank: Tapentadol (DB06204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50, 100, 150, 200, 250 mg twice daily for 15 weeks
Study: NCT00449176
Drug: oxycodone CR
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10, 20, 30, 40, 50 mg twice daily for 15 weeks
Study: NCT01621854
Drug: NUC-1031
Normalized name: NUC-7738
DrugBank: NUC-7738 (DB19148)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort 1, Schedule A, NUC-1031 I.V. 1000mg/m2, Days 1, 8, \& 15 every 28 days Cohort 1, Schedule B, NUC-1031 I.V. 500mg/m2, Days 1 \& 5, 8 \& 12, 15 \&19 every 28 days Cohort 2, Schedule A, NUC-1031 I.V. 2000mg/m2, Days 1, 8, \& 15 every 28 days Cohort 2, Schedule B, NUC-1031 I.V. 1000mg/m2, Days 1 \& 5, 8 \& 12, 15 \&19 every 28 days
Study: NCT00370877
Drug: rFVIIa
Normalized name: rFVIIa
DrugBank: Coagulation factor VIIa Recombinant Human (DB00036)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients included in this arm of the study will recieve standard care for post-partum hemorrhage plus a slow intravenous injection (2ml/min) of rFVIIa (60µg/kg)
Study: NCT00594867
Drug: Aspirin - 325 mg per day + Placebo
Normalized name: aspirin 325 MG
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin - 325 mg per day + Placebo
Study: NCT02107131
Drug: Intravitreal ranibizumab 0.3mg
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02515279
Drug: Peginterferon alfa-2a
Normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 180 micrograms subcutaneous weekly for 48 weeks.
Study: NCT02515279
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000-1600 mg day orally for 48 weeks.
Study: NCT02472964
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 80mg/m2 IV over 60 minutes weekly.
Study: NCT02472964
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 75mg/m2 IV over 60 minutes on day 1 of a 3 week cycle
Study: NCT00042562
Drug: duloxetine
Normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00901381
Drug: Filgrastim
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 10 µg/kg subcutaneously once daily x 5 days
Study: NCT02217930
Drug: WCK 2349
Normalized name: Wck 771 free base
DrugBank: Levonadifloxacin (DB16219)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02217930
Drug: Moxifloxacin
Normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00490893
Drug: Detemir
Normalized name: Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00244296
Drug: Duloxetine hydrochloride
Normalized name: Duloxetine Hydrochloride
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00689221
Drug: Cilengitide
Normalized name: Cilengitide
DrugBank: Cilengitide (DB11890)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilengitide 2000 milligram (mg) will be administered intravenously twice weekly over 1 hour infusion from Weeks -1 to 77 or until occurrence of progressive disease, unacceptable toxicity, or withdrawal for any other reason. If considered beneficial in the opinion of the Investigator, continuation of cilengitide treatment will be optional in subjects without disease progression and after Week 77 since start of treatment.
Study: NCT00689221
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide (TMZ) 75 milligram per square meter \[mg/m\^2\] will be administered intravenously once daily from Weeks 1 to 6. From Week 11 onwards, TMZ will be given as maintenance treatment at a dose of 150-200 mg/m\^2 for consecutive 5 days every 4 weeks until Week 34 or until disease progression.
Study: NCT01749982
Drug: Betaine
Normalized name: betaine
DrugBank: Betaine (DB06756)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00318773
Drug: sertraline
Normalized name: Sertraline
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 - 100 mg daily for 2 weeks before each menses for 4 months or 12 months and then switched to placebo.
Study: NCT04166253
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfacalcidol oral tablets once daily
Study: NCT03579030
Drug: RTA 1701 capsules
Normalized name: RTA 744
DrugBank: RTA 744 (DB05920)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule containing RTA 1701, multiple dosages
Study: NCT02685657
Drug: Drug: Selumetinib
DrugBank: Selumetinib (DB11689)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02685657
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03696940
Drug: L-Carnitine 500Mg Oral Tablet + Atorvastatin 10 mg
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of 2 tablets of atorvastatin 10 mg (each one) every 24 hours for 6 months.
Study: NCT03696940
Drug: Atorvastatin 10mg
Normalized name: AMLODIPINE 5MG/ATORVASTATIN 10MG TAB
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of 2 tablets atorvastatin 10 mg (each one) every 24 hours for 6 months.
Study: NCT01768312
Drug: Cyclosporine ophthalmic solution
Normalized name: cycloSPORINE Ophthalmic Solution
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop twice/day for 12 weeks to both eyes
Study: NCT02679261
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration atorvastatin 20 mg per day
Study: NCT00322348
Drug: Goserelin acetate
Normalized name: Goserelin Acetate
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3.6 mg intramuscular depot injection given every 4 weeks
Study: NCT00322348
Drug: Goserelin acetate
Normalized name: Goserelin Acetate
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10.8 mg intramuscular depot injection given every 12 weeks
Study: NCT01239030
Drug: Methylphenidate Hydrochloride Extended Release Capsules
Normalized name: methylphenidate hydrochloride Extended Release Suspension
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Biphentin Methylphenidate ER Once-A-Day Capsules
Study: NCT00809887
Drug: Micafungin lock therapy
DrugBank: Micafungin (DB01141)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01922076
Drug: Adavosertib
Normalized name: Adavosertib
DrugBank: Adavosertib (DB11740)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT02316964
Drug: decitabine
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg/m2 Given IV (intravenous) for 5 days over 60 minutes
Study: NCT01405482
Drug: Botulinum Toxin Type A
Normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Botulinum Toxin Type A 100 units injected under EMG guidance one time into the anterior,middle scalenes and pectoralis minor muscle
Study: NCT00434382
Drug: Sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00434382
Drug: Isoflurane
Normalized name: Isoflurane
DrugBank: Isoflurane (DB00753)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00434382
Drug: Desflurane
Normalized name: Desflurane
DrugBank: Desflurane (DB01189)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00434382
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00434382
Drug: Alfentanil
Normalized name: Alfentanil
DrugBank: Alfentanil (DB00802)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00859079
Drug: GLP-1
Normalized name: rGLP-1
DrugBank: rGLP-1 (DB05433)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients received GLP-1 intravenously at a dose of 1.2 pmol/kg/min for at maximum 8 hours.
Study: NCT00010179
Drug: lurtotecan liposome
Normalized name: Lurtotecan
DrugBank: Lurtotecan (DB12222)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04259086
Drug: DaxibotulinumtoxinA for injection
Normalized name: daxibotulinumtoxinA-lanm
DrugBank: DaxibotulinumtoxinA (DB17929)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection
Study: NCT01850979
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tacrolimus 0,03% eyedrops (olive oil vehicle) every 12 hours for 3 months placebo : olive oil eyedrops every 12 hours for 3 months
Study: NCT01850979
Drug: Olive Oil
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients in this groups receive eye drops containing olive oil (vehicle of tacrolimus eye drops) twice a day (every 12 hours) for 90 days.
Study: NCT00141154
Drug: Loxoprofen
Normalized name: Loxoprofen
DrugBank: Loxoprofen (DB09212)
Approvals — FDA: no, EMA: no, PMDA: yes
Study: NCT00410033
Drug: insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01441102
Drug: Dextromethorphan hydrobromide
Normalized name: Dextromethorphan Hydrobromide
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants instructed to take 60 mg dextromethorphan capsules orally two times a day for 24 months.
Study: NCT02530489
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02530489
Drug: Nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT03215797
Drug: phenylephrine
Normalized name: Phenylephrine
DrugBank: Phenylephrine (DB00388)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: phenylephrine 100ug/ml IV infusion at a rate of 5ml/h in case of hypotension.
Study: NCT02848248
Drug: SGN-CD123A
Normalized name: Moab, chimeric, SGN-30, to CD30 antigen
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous infusion in 3-week cycles
Study: NCT01830127
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 24 Weeks
Study: NCT01830127
Drug: BI 207127 high dose
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 Weeks
Study: NCT01830127
Drug: Faldaprevir
Normalized name: Faldaprevir
DrugBank: Faldaprevir (DB11808)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 Weeks
Study: NCT01830127
Drug: BI 207127 low dose
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 Weeks
Study: NCT01159054
Drug: Extended Release Nicotinic Acid (Niaspan)
Normalized name: NICOTINIC ACID
DrugBank: Niacin (DB00627)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will start on 500 mg per day of Niaspan for 4 weeks, then the dose will be increased to 1000 mg per day of Niaspan for 4 weeks, then the dose will be increased to 1500 mg of Niaspan per day for 4 weeks, after this subjects with weight of less than 60 kg will continue at 1500 mg per day of Niaspan for another 12 weeks whereas in subjects with weight of more than 60 kg the dose will be increased to 2000 mg of Niaspan per day which will be continued for 12 weeks.
Study: NCT03088826
Drug: Morphine Sulfate
Normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15mg PO morphine sulfate
Study: NCT03088826
Drug: Oxycodone
Normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10mg Oxycodone
Study: NCT01527734
Drug: Tetrodotoxin
Normalized name: Tetrodotoxin
DrugBank: Tetrodotoxin (DB05232)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15ug and 30ug once or twice a day for 1 or 2 days.
Study: NCT04492475
Drug: Interferon beta-1a
Normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rebif (R) is a purified 166 amino acid human interferon beta glycoprotein with an amino acid sequence identical to natural fibroblast derived human interferon beta. Each 0.5 mL prefilled syringe contains 44 mcg of interferon beta-1a, 4 mg human albumin, USP; 27.3 mg mannitol, USP; 0.4 mg sodium acetate; and water for injection, USP.
Study: NCT03306212
Drug: Botulinum toxin A
Normalized name: Botulinum toxin A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Study: NCT04021238
Drug: Perflutren lipid microsphere
Normalized name: perflutren lipid microspheres
DrugBank: Perflutren (DB00556)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Baseline B-mode US will be performed to confirm the lesions being imaged (unless it is a subject with no lesions, then a basic B-mode US will be performed. Perflutren is a diagnostic drug that is intended to be used for contrast enhancement. The vial contains a clear, colorless, sterile, non-pyrogenic, hypertonic solution which is activated by mechanical agitation with Vialmix®.It will be dispensed in inactivated form to a study team member. The contrast agent will be activated just prior to administration (ideally to be used within 5 minutes of activation). Contrast agent Definity (or Lumason) will be activated according to package insert instructions, including use of VialMix®, the device used to activate Definity. Administration will occur IV in coordination with sonography staff trained specifically in contrast ultrasound imaging.The total imaging time is anticipated to be less than 30 minutes.
Study: NCT00912548
Drug: goserelin
Normalized name: Goserelin
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1. Zoladex™ administration:~   Zoladex™ depot is available as a sterile disposable syringe. The depot is administered subcutaneously under the abdominal skin under sterile conditions. If necessary the injection site may be pre-treated with a local anaesthetic.~2. Sequence of administration Zoladex depot:~   The substance is administered for 24 months (2 years) at 28-day intervals (a period of 34 days between 2 administrations must not be exceeded).~3. Dosage:~   Each depot contains 3.6mg Zoladex. The substance Zoladex is contained in a while cylindrical rodlet .~4. Storage instructions for Zoladex™ Zoladex™ is kept a room temperature.
Study: NCT00912548
Drug: tamoxifen
Normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1. Dose and period of Tamoxifen therapy:~   Tamoxifen is administered in tablet form. Each day 2 X 10 mg or 1 X 20 mg Tamoxifen are taken in the form of the respective tablet.~2. Storage instructions for Tamoxifen Tamoxifen is stored at room temperature away from light.
Study: NCT01400503
Drug: Siltuximab
Normalized name: Siltuximab
DrugBank: Siltuximab (DB09036)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Type=exact number, unit=mg/kg, number=11, form=intravenous solution, route=intravenous. Siltuximab given as a 1-hour infusion every 3 weeks.
Study: NCT01417026
Drug: Intranasal Oxytocin (Trade name: Syntocinon)
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This is a double-blind placebo-controlled trial of intranasal oxytocin in children and adolescents with ASD. Subjects will be randomized to 24 IU intranasal oxytocin or placebo for a 5 day period with concomitant game play of computer games, which are designed to enhance face perception skills. Measures of social function and cognition will be administered before and after the intervention period.
Study: NCT00091481
Drug: Zemplar
Normalized name: Zemplar
DrugBank: Paricalcitol (DB00910)
Approvals — FDA: yes, EMA: no, PMDA: no